Inhibiting C5 in patients with severe COVID-19—the incorrect target?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibiting C5 in patients with severe COVID-19—the incorrect target?

Published:2023-09 Issue:9 Volume:11 Page:e80
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Lim Endry H T,Vlaar Alexander P J,Brouwer Matthijs C,van de Beek Diederik

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference5 articles.

1. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial;Annane;Lancet Respir Med,2023

2. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial;Vlaar;Lancet Respir Med,2022

3. Complement activation in COVID-19 and targeted therapeutic options: a scoping review;Lim;Blood Rev,2023

4. Complement inhibition in severe COVID-19—blocking C5a seems to be key: author's reply;Annane;EClinicalMedicine,2021

5. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19;Vlaar;Clin Transl Sci,2022

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug reactions associated with COVID-19 management;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-14

2. Targeting C5a is beneficial in critically ill COVID-19 patients;Immunobiology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP